

Van Herk Investments notify of 5.3% shareholding in Galapagos

Mechelen, Belgium; 6 January 2014 – Galapagos NV (Euronext: GLPG) received notice that Van Herk Investments currently holds 5.3% of outstanding Galapagos shares.

Pursuant to Belgian transparency legislation¹, Galapagos received notice on 31 December 2013 from Van Herk Investments B.V., stating that they held 1,586,727 shares. This represents 5.3% of the 29,794,046 Galapagos shares currently outstanding and marks the first transparency notice that Galapagos has received from Van Herk Investments.

About Van Herk Investments

Part of the Van Herk Group of companies, Van Herk Investments is invested in listed and private companies. Van Herk Investments has a global orientation, with holdings in construction, project development, biotechnology and life sciences, financial services, and energy sectors. Current biotechnology and life sciences holdings include Agendia, ART, BioInvent, CardioGenX, Galapagos, Nightbalance, SkylineDx and VitalNext. More information at www.vanherkgroep.nl

About Galapagos

[Galapagos](#) (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action, with a large pipeline comprising of six Phase 2 studies (three led by GSK), one Phase 1 study, five pre-clinical, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and other indications.

AbbVie and Galapagos signed an agreement in CF where they work collaboratively to develop and commercialize oral drugs that address two mutations in the CFTR gene, the G551D and F508del mutation. Potentiator GLPG1837 is at the pre-clinical candidate stage. In the field of inflammation, AbbVie and Galapagos signed a worldwide license agreement whereby AbbVie will be responsible for further development and commercialization of [GLPG0634](#) after Phase 2B. GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2B studies in RA and about to enter Phase 2 studies in Crohn's disease. Galapagos has another selective JAK1 inhibitor in Phase 2 in ulcerative colitis, psoriasis, and lupus, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012). [GLPG0974](#) is the first inhibitor of FFA2 to be evaluated clinically for the treatment of IBD; this program is currently in a Proof-of-Concept Phase 2 study. [GLPG1205](#) is a first-in-class molecule that targets inflammatory disorders and has completed Phase 1 studies.

The Galapagos Group, including fee-for-service companies [BioFocus](#), [Argenta](#) and [Fidelta](#), has around 800 employees and operates facilities in five countries, with global headquarters in Mechelen, Belgium. Further information, including an updated major shareholder overview, can be found at: www.glpg.com

¹ Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market.

Contact

Galapagos NV
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com

Galapagos forward-looking statements

This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.